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OBJECTIVES: The clinical significance of portal hypertensive gastropathy (PHG) in patients with compensated liver
disease is not well established. The aim of this study was to determine the prevalence and
correlates of PHG in a large cohort of patients with chronic hepatitis C virus (HCV) infection and
bridging fibrosis/compensated cirrhosis entering the randomized phase of the Hepatitis C Antiviral
Long-term Treatment against Cirrhosis trial (HALT-C).
METHODS: The presence and severity of PHG in 1,016 HCV patients with no prior history of gastrointestinal
bleeding was determined at surveillance endoscopy using the New Italian Endoscopy Club criteria.
RESULTS: Overall, 37% of HALT-C patients had PHG with 34% having mild and 3% with severe changes. The
mucosal mosaic pattern was identified in 33%, red marks in 15%, and gastric antral vascular
ectasia (GAVE) features in only 3%. Independent correlates of PHG included biochemical markers of
liver disease severity (lower serum albumin, higher bilirubin), portal hypertension (lower platelet
count), insulin resistance (higher glucose), and non-African American race. Independent correlates
of GAVE included a history of smoking, nonsteroidal anti-inflammatory drugs (NSAIDs) use within
the past year, and higher serum bilirubin and glucose levels. There was a strong positive association
between the presence of PHG and esophageal varices ( p < 0.0001).
CONCLUSIONS: PHG is associated with the histological and biochemical severity of liver disease in patients with HCV
and advanced fibrosis but is mild in most patients. The clinical relevance of these findings will be
further explored during the randomized phase of the HALT-C study.
(Am J Gastroenterol 2006;101:983–992)
INTRODUCTION
Portal hypertensive gastropathy (PHG) is an endoscopic ab-
normality of the gastric mucosa that is most commonly ob-
This is publication #12 from the HALT-C Trial Group.
served in patients with advanced liver disease and/or portal
hypertension (1, 2). This endoscopic lesion is characterized
by the presence of a mucosal mosaic pattern with a snake
skin-like appearance, focal red and brown spots, and vascu-
lar ectasias localized to the fundus or body of the stomach
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(2–5). The severity of PHG is commonly graded as mild or
severe but the condition is very dynamic and some patients
spontaneously improve while others worsen despite no appar-
ent change in liver disease status (4–7). Ligation of varices
and sclerotherapy have been associated with the development
of de novo PHG in up to 50% of patients during short-term
follow-up (8, 9). Patients with PHG are at increased risk of
acute as well as chronic gastrointestinal bleeding although
the annual incidence of bleeding has been difficult to quan-
tify and distinguish from that due to esophagogastric varices
(6, 7, 10).
Prior studies have suggested that PHG is more common
in patients with decompensated cirrhosis compared to those
with compensated liver disease (2, 6, 11). However, most
of these studies were of limited size and included patients
with varying etiologies of liver disease (2, 6). The aim of
the current study was to determine the prevalence of PHG
in a large cohort of well-characterized patients with chronic
hepatitis C and biopsy proven bridging fibrosis or cirrho-
sis who were enrolled in the Hepatitis C Antiviral Long-
term Treatment against Cirrhosis trial (HALT-C). In addi-
tion, we set out to identify baseline laboratory and clinical
features associated with the presence and severity of PHG.
Finally, we determined the relationship between esophageal
varices and PHG in this large cohort of patients without




This study included all patients entering the randomized
phase of the HALT-C trial who underwent a screening esoph-
agogastroduodenoscopy (EGD). Before enrollment, all sub-
jects signed a written informed consent that had been ap-
proved by the local Institutional Review Boards at each of
the 10 participating sites (12). The data were analyzed at
the data coordinating center (New England Research In-
stitute, Boston, MA). The entry and exclusion criteria for
the HALT-C trial have been previously published (12, 13).
Briefly, all HALT-C patients had detectable hepatitis C virus
(HCV) RNA, a liver biopsy within 12 months of entry demon-
strating an Ishak fibrosis score of 3 or 4 (bridging fibrosis)
or 5–6 (cirrhosis), and nonresponse to prior interferon ther-
apy. Subjects with a Child-Turcotte-Pugh score of >6 or a
prior history of variceal/portal hypertensive bleeding, ascites,
or hepatic encephalopathy were excluded. Enrolled subjects
were retreated with pegylated Interferonα2a (180 μg/wk;
PegasysTM, Roche Laboratories, Nutley NJ) and ribavirin
(1,000–1,200 mg daily, CopegusTM, Roche). Those with per-
sistently detectable HCV RNA at week 20 were eligible for
randomization to either pegylated Interferonα2a 90 μg/wk
or observation without therapy for the next 3.5 yr. Week
20 virologic responders received a full 48-wk course of pegin-
terferon and ribavirin. Patients with virologic breakthrough
during treatment or those with relapse after week 48 were also
eligible for randomization. In addition, subjects with Ishak
3–6 fibrosis who had failed to respond to at least 24 wk of
pegylated interferon and ribavirin given outside of the trial,
referred to as “Express” patients, were eligible for random-
ization.
A pretreatment medical history and physical exam was
performed before enrollment. Lifetime alcohol consumption
was assessed using a modified Skinner survey (14). All liver
biopsies were evaluated by a central group of pathologists and
the degree of hepatic fibrosis and inflammation were defined
using the Ishak scoring system (15). Fasting insulin and glu-
cose levels were obtained in all patients except the Express
group. Insulin resistance was determined by the homeostatic
model (IRHOMA) (16). Splenomegaly was defined as a spleen
length >13 cm on sonography.
Endoscopy
The protocol for EGD including the criteria for PHG grading
was written in a manual of procedures and members at all
centers were trained on the PHG scoring system before study
initiation. The presence and severity of PHG were scored
by the local study endoscopist according to the New Italian
Endoscopy Conference criteria (NIEC) on a standard form
(4). Specifically, the mucosal mosaic pattern was considered
mild and scored 1 if there were diffuse pink polygonal, scale-
like areas and severe with a score of 2 if present throughout
the mucosa. Focal flat or slightly bulging red marks were
considered mild and scored 1 if found in isolated areas and
severe with a score of 2 if present throughout the mucosa.
Gastric antral vascular ectasia (GAVE) was diagnosed by the
presence of flat or slightly raised, red stripe-like lesions radi-
ating from the pylorus to the antrum and body of the stom-
ach and given a score of 2. The presence of black-brown
spots representative of old submucosal hemorrhage were not
recorded. A PHG score of 1–3 was considered mild PHG
while a score of 4 or more was considered severe PHG (4).
The presence and size of esophageal varices were graded
as small (F1) when they impinged on 25% of the lumen,
medium (F2) when between F1 and F3, and large (F3) if
the varices impinged on >50% of the lumen. Other find-
ings such as the presence of a hiatal hernia, gastric ulcer,
and duodenal ulcer were reported in a text field by the local
endoscopist.
Statistical Analysis
Continuous variables with non-normal distribution were log
transformed. Univariate analysis of demographic, liver dis-
ease, and clinical factors as correlates of the presence and
severity of PHG and its component features were under-
taken. In addition, multivariate logistic regression analysis
with stepwise selection of significant independent predictors
was performed to identify independent correlates of the pres-
ence and severity of PHG as well as GAVE.
Portal Hypertensive Gastropathy 985
RESULTS
Patient Population
A total of 1,050 subjects were enrolled in the randomized
phase of the HALT-C trial of whom 1,016 (97%) underwent
EGD and were included in this study (Table 1). The mean
age of participants was 50.2 yr, there was a preponderance of
men (71%), and 18% were African American. The majority
of subjects were abstinent from alcohol (86%) and cigarettes
(70%) at enrollment. Forty-nine percent of subjects reported
use of nonsteroidal anti-inflammatory drugs (NSAIDs) dur-
ing the 12 months prior to their endoscopy while only 14%
were receiving a proton pump inhibitor (PPI) and 5% a cyclo-
Table 1. Clinical Features of the HALT-C Study Population
Parameter All Subjects N = 1,016 Ishak 3 or 4 N = 598 Ishak 5 or 6 N = 418 Ishak 3/4 vs 5/6 p Value∗
Age (yr) 50.2 + 7.2 50.2 + 7.3 50.2 + 7.0 0.84
Females (%) 29 30 28 0.43
African American (%) 18 20 16 0.046
Lead-in (%) 63 61 65 0.08
Breakthrough/relapse (%) 14 17 11
Express (%) 23 22 24
No alcohol for 6 months (%) 86 84 89 0.027
Lifetime alcohol/day (g/day) 25.8 + 40.2 24.9 + 39.4 26.9 + 41.4 0.44
No smoking for 6 months (%) 70 71 70 0.65
Lifetime smoking (pack yr) 14.8 + 16.7 15.1 + 16.8 14.5 + 16.6 0.61
Splenomegaly (%) 33 24 47 <0.001
Body mass index (kg/m2) 29.9 + 5.5 29.7 + 5.6 30.3 + 5.3 0.064
Diabetes mellitus (%) 24 22 28 0.019
Hypertension (%) 35 33 37 0.27
Log10 IRHOMA
† 2.28 + 0.92 2.18 + 0.94 2.43 + 0.88 0.0002
Log10 IRHOMA(nondiabetic)
† 2.01 + 0.75 1.93 + 0.78 2.14 + 0.68 0.001
Log10 glucose 4.65 + 0.3 4.63 + 0.29 4.68 + 0.3 0.0164
Log10 glucose (nondiabetic) 4.53 + 0.14 4.52 + 0.15 4.54 + 0.13 0.121
Log10 insulin 3.63 + 0.75 3.55 + 0.77 3.75 + 0.70 0.0002
Log10 insulin (nondiabetic) 3.49 + 0.69 3.42 + 0.71 3.60 + 0.64 0.0014
Log10 HCV RNA 14.8 + 1.2 15.0 + 1.2 14.5 + 1.3 <0.0001
HCV genotype 1 (%) 94 94 93 0.28
Duration of infection (yr) 28 + 8 28 + 8 29 + 8 0.086
Ishak inflammation 7.5 + 2.0 7.2 + 2.0 8.0 + 2.0 <0.001
Mallory bodies (%) 15 11 22 <0.001
Hemoglobin (g/dL) 15.0 + 1.4 15.1 + 1.5 14.9 + 1.4 0.022
Platelets (103/mL) 165 + 66 187 + 62 134 + 55 <0.001
Iron saturation (%) 36 + 16 38 + 18 35 + 15 0.0014
Log10 ferritin (ng/mL) 2.36 + 0.47 2.36 + 0.47 2.35 + 0.48 0.89
Serum AST (× ULN) 2.1 + 1.5 1.9 + 1.3 2.4 + 1.6 <0.001
Serum ALT (× ULN) 2.1 + 1.6 2.0 + 1.6 2.3 + 1.6 0.020
AST: ALT ratio 0.88 + 0.29 0.84 + 0.28 0.94 + 0.31 <0.001
Alkaline phosphatase (× ULN) 0.85 + 0.42 0.80 + 0.42 0.93 + 0.42 <0.001
Bilirubin (mg/dL) 0.79 + 0.40 0.72 + 0.35 0.89 + 0.45 <0.001
INR 1.04 + 0.11 1.01 + 0.10 1.08 + 0.10 <0.001
Albumin (g/dL) 3.87 + 0.40 3.95 + 0.35 3.76 + 0.43 <0.001
Biopsy to EGD (days) 287 + 192 302 + 197 265 + 183 0.0024
NSAID at EGD (%) 9 10 9 0.70
NSAID within 12 months (%) 49 50 47 0.39
COX-2 at EGD (%) 5 5 5 0.72
Beta-blocker at EGD (%) 9 9 10 0.41
PPI at EGD (%) 14 14 14 0.92
Data presented as mean ± SD or (%).
∗T-tests were used to compare means and χ2 for proportions of patients with Ishak 3/4 vs Ishak 5/6.
†Tested in only 776 non express patients.
oxygenase type 2 (COX-2) inhibitor at the time of EGD. As
expected, there was an overrepresentation of HCV genotype 1
in this group of nonresponders to prior pegylated interferon
and ribavirin. The mean body mass index (BMI) was 29.9
kg/m2 and 24% of subjects were diabetic.
There were 598 subjects (58%) with Ishak stage 3 or 4
fibrosis and 418 subjects (42%) with Ishak stage 5 or 6
fibrosis. The proportion of patients with diabetes mellitus,
Mallory bodies on biopsy, and the mean Ishak inflammatory
scores were significantly higher in subjects with cirrhosis
compared to those with bridging fibrosis. Conversely, sub-
jects with bridging fibrosis had significantly higher platelet
counts and albumin levels and lower serum bilirubin, alanine
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Figure 1. Prevalence of mild and severe portal hypertensive gas-
tropathy (PHG) and component features in HALT-C patients.
and aspartate aminotransferase (ALT, AST), alkaline phos-
phate, and INR levels compared to subjects with cirrhosis.
Prevalence of PHG
Overall, 374 subjects (37%) had PHG identified at surveil-
lance EGD. In the majority of cases, PHG was mild (34%) and
only 29 patients (3%) had severe changes. The most frequent
endoscopic feature suggestive of PHG was the presence of
mucosal mosaic pattern which was seen in 33% of subjects
(Fig. 1). In contrast, isolated or confluent red marks were
reported in 15% of subjects and GAVE features were noted
in only 3%. If GAVE features were present, the subject was
more likely to have severe PHG compared to subjects with
PHG and no GAVE lesions (odds ratio = 40.4 (15.9, 101.9)
p < 0.0001).
Both mild and severe PHG were significantly associated
with the stage of hepatic fibrosis (Fig. 2, p < 0.0001 for
trend). The mean levels of several biochemical markers of
liver disease severity (i.e., albumin, bilirubin, and INR) were
also significantly worse among subjects with PHG compared
to those without PHG (Table 2). Similarly, the mean Ishak
fibrosis scores and the prevalence of splenomegaly were sig-
Figure 2. Proportion of patients with chronic hepatitis C and Ishak
fibrosis scores of 3–6 with mild or severe portal hypertensive gas-
tropathy (PHG) ( p < 0.0001 for trend).
nificantly higher among those with PHG compared to those
without PHG. Interestingly, Mallory bodies were more fre-
quently noted in subjects with PHG. In addition, the IRHOMA
and glucose levels were significantly higher among subjects
with PHG and these differences were most pronounced in
nondiabetic patients. However, the prevalence of diabetes
and mean BMI levels were not significantly greater in sub-
jects with PHG compared to subjects without PHG. PHG was
less frequently identified in African American patients (35%)
compared to others (39%) ( p = 0.037).
Although we had anticipated that lifetime smoking and al-
cohol consumption would be associated with PHG, neither of
these measures showed a significant association. In addition,
use of NSAIDs, PPIs, COX-2 inhibitors, and beta-blockers
at the time of EGD was not associated with PHG. Finally, the
mean hemoglobin levels and iron stores of subjects with PHG
were not significantly different from those without PHG.
Correlates of PHG
On univariate analysis, serum alkaline phosphatase,
AST/ALT ratio, splenomegaly, INR, bilirubin, log10 IRHOMA,
and log10 glucose levels were all associated with a greater
likelihood of PHG. In contrast, African American race,
serum albumin, and platelet counts were associated with a
lower frequency of PHG. Using stepwise logistic regression,
non-African American race, albumin, platelets, bilirubin,
and log10 glucose were independently associated with PHG
(Table 3). However, the overall model c-statistic was only
0.645 and the majority of the variance was accounted for by
low platelet count. Models with similar predictive ability were
obtained when assessing the presence of PHG in patients with
bridging fibrosis and cirrhosis separately (data not shown).
Positive correlates of severe PHG in the overall cohort in-
cluded AST/ALT ratio, bilirubin, Ishak fibrosis score, and
log10 glucose levels while platelet counts were negatively as-
sociated with severe PHG. Using logistic regression analysis,
only log10 glucose and total bilirubin levels were significant
independent correlates of severe PHG (Table 3).
Since GAVE features are most commonly associated with
gastrointestinal bleeding, models to predict these changes
were derived. On univariate analysis, smoking history, biliru-
bin, Ishak fibrosis score, NSAID use in the past 12 months,
and log10 glucose were positively associated with GAVE
while platelet count and time from biopsy to endoscopy were
negatively associated with GAVE. When using stepwise se-
lection, we identified bilirubin, NSAID use, smoking history,
and log10 glucose as independent correlates of GAVE. How-
ever, the prevalence of GAVE in the study population was low
(3%) and additional studies in patients with a higher preva-
lence of GAVE are needed to confirm the relatively weak
associations noted.
Esophageal Varices and PHG
Previous studies have suggested a positive relationship be-
tween the presence of esophageal varices and PHG (2, 9).
Studies of the HALT-C cohort have shown that 26% of
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Table 2. HALT-C Patients with and Without Portal Hypertensive Gastropathy
Parameter All Subject N = 1,016 No. PHG N = 637 PHG Present N = 374 Odds Ratio∗ (95% CI) p Value∗
Age (yr) 50.2 + 7.2 50.2 + 7.4 50.2 + 6.6 1.00 (0.88, 1.14) 1.000
Females (%) 29 30 28 0.87 (0.66, 1.16) 0.352
African American (%) 18 21 15 0.68 (0.48, 0.96) 0.027
Lead-in (%) 63 62 64 0.91
Breakthrough/relapse (%) 14 15 14
Express (%) 23 23 22
No alcohol for 6 months (%) 86 87 84 0.82 (0.57, 1.17) 0.272
Lifetime alcohol/day (g/day) 25.8 + 40.2 24.9 + 39.4 26.9 + 41.4 1.03 (0.90, 1.17) 0.67
No smoking for 6 months (%) 70 72 68 1.21 (0.91, 1.59) 0.19
Lifetime smoking (pack yr) 14.8 + 16.7 15.1 + 16.8 14.5 + 16.6 1.08 (0.95, 1.23) 0.24
Splenomegaly (%) 33 30 39 1.45 (1.10, 1.90) 0.0075
Body mass index (kg/m2) 29.9 + 5.5 29.7 + 5.6 30.3 + 5.3 1.03 (0.91, 1.17) 0.64
Diabetes Mellitus (%) 24 23 27 1.27 (0.94, 1.70) 0.12
Hypertension (%) 35 34 35 1.05 (0.80, 1.37) 0.73
Log10 IRHOMA
† 2.28 + 0.92 2.23 + 0.91 2.38 + 0.93 1.18 (1.02, 1.37) 0.025
Log10 IRHOMA(nondiabetic)
† 2.01 + 0.75 1.97 + 0.76 2.08 + 0.72 1.16 (0.98, 1.37) 0.297
Log10 glucose 4.65 + 0.30 4.63 + 0.30 4.68 + 0.3 1.18 (1.04, 1.34) 0.01
Log10 glucose (nondiabetic) 4.53 + 0.14 4.52 + 0.15 4.55 + 0.13 1.21 (1.04, 1.41) 0.0095
Log10 insulin 3.63 + 0.75 3.59 + 0.74 3.70 + 0.75 1.15 (0.99, 1.33) 0.060
Log10 insulin (nondiabetic) 3.49 + 0.69 3.46 + 0.70 3.54 + 0.67 1.14 (0.96, 1.35) 0.14
Log10 HCV RNA 14.8 + 1.2 15 + 1.1 14.5 + 1.3 0.89 (0.79, 1.01) 0.071
HCV genotype 1 (%) 94 94 93 0.88 (0.52, 1.48) 0.63
Duration of infection (yr) 28.1 + 8.0 27.7 + 8.0 28.6 + 8.1 1.05 (0.92, 1.20) 0.44
Ishak fibrosis score 4.1 + 1.2 3.9 + 1.2 4.4 + 1.3 1.40 (1.26, 1.56) <0.0001
Ishak inflammation 7.5 + 2.0 7.2 + 2.0 8.0 + 2.0 1.19 (1.05, 1.36) 0.006
Mallory bodies (%) 15 12 20 1.77 (1.25, 2.50) 0.0011
Hemoglobin (g/dL) 15.0 + 1.4 15.1 + 1.5 14.9 + 1.4 1.03 (0.91, 1.18) 0.62
Platelets (103/mL) 164 + 65 186 + 63 134 + 57 0.64 (0.55, 0.74) <0.0001
Iron saturation (%) 36 + 16 38 + 18 35 + 15 1.07 (0.95, 1.22) 0.29
Log10 ferritin (mg/dL) 2.36 + 0.47 2.36 + 0.48 2.35 + 0.45 0.99 (0.87, 1.12) 0.84
Serum AST (× ULN) 2.1 + 1.5 1.87 + 1.33 2.43 + 1.64 1.13 (0,99, 1.29) 0.061
Serum ALT (× ULN) 2.14 + 1.63 2.04 + 1.64 2.28 + 1.61 1.04 (0.92, 1.18) 0.53
AST: ALT ratio 0.88 + 0.29 0.84 + 0.28 0.94 + 0.42 1.25 (1.10, 1.42) 0.0005
Alkaline phosphatase (× ULN) 0.85 + 0.42 0.80 + 0.42 0.93 + 0.42 1.19 (1.05, 1.36) 0.0069
Bilirubin (mg/dL) 0.79 + 0.4 0.72 + 0.35 0.89 + 0.42 1.40 (1.23, 1.60) <0.0001
INR 1.04 + 0.11 1.01 + 0.10 1.08 + 0.10 1.40 (1.22, 1.60) <0.0001
Albumin (g/dL) 3.87 + 0.4 3.95 + 0.4 3.8 + 0.4 0.72 (0.63, 0.82) <0.0001
Biopsy to EGD (days) 287 + 192 302 + 197 265 + 183 1.00 (0.88, 1.14) 0.94
NSAID at EGD (%) 9 9 10 1.09 (0.70, 1.70) 0.71
NSAID within 12 months (%) 49 51 46 0.82 (0.63, 1.06) 0.13
COX-2 at EGD (%) 5 5 5 1.06 (0.58, 1.93) 0.86
Beta-blocker at EGD (%) 9 8 11 1.47 (0.94, 2.28) 0.087
PPI at EGD (%) 14 15 14 0.93 (0.63, 1.36) 0.69
Data presented as mean + SD or (%).
PPI = proton pump inhibitor; PHG = portal hypertensive gastropathy.
∗Comparison of subjects with and without portal hypertensive gastropathy.
†Tested in only 776 nonexpress patients.
patients had esophageal varices and that varices were sig-
nificantly more common in subjects with cirrhosis compared
to those with bridging fibrosis (39% vs 16%, p < 0.0001)
(17). For these reasons, the positive association between
the presence of PHG and esophageal varices was not un-
expected (Fig. 3). A total of 40% of patients with PHG had
varices compared to only 17% of subjects without PHG ( p
< 0.0001). In addition, subjects with PHG were significantly
more likely to have medium or large varices compared to sub-
jects without PHG (odds ratio = 6.40 (95% CI: 3.47, 11.79), p
< 0.0001).
Additional Endoscopic Findings
A hiatal hernia was identified in 162 subjects (16%), a gastric
ulcer was noted in 18 subjects (1.8%), a duodenal ulcer in 16
(1.6%), and 5 of these subjects had both a gastric and a duo-
denal ulcer. There was a trend toward PHG being associated
with the presence of a gastric ulcer and duodenal ulcer but
neither trend was statistically significant. However, drinking
alcohol in the past 6 months was positively associated with the
presence of a gastric ulcer ( p = 0.016). Similarly, drinking
alcohol in the past 6 months ( p = 0.043), NSAID use
in the past 12 months ( p = 0.035), and the presence of
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Table 3. Logistic Regression Models to Predict Portal Hypertensive Gastropathy, Severe Portal Hypertensive Gastropathy, and Gastric Antral
Vascular Ectasia
Variable Estimate Odds Ratio (95% CI) p Value c Statistic
Portal hypertensive gastropathy
African American −0.434 0.65 (0.45, 0.93) 0.020 0.645
Platelets −0.00407 0.99 (0.99, 0.998) 0.0007
Bilirubin 0.570 1.77 (1.24, 2.51) 0.0015
Albumin −0.627 0.53 (0.37, 0.76) 0.0005
Log10 glucose 0.548 1.73 (1.10, 2.71) 0.017
Severe portal hypertensive gastropathy
Bilirubin 1.01 2.75 (1.40, 5.37) 0.0031 0.678
Log10 glucose 1.67 5.29 (2.07, 13.6) 0.0005
Gastric antral vascular ectasia
Bilirubin 0.947 2.58 (1.36, 4.88) 0.0037 0.702
NSAID within 12 months 0.703 2.02 (1.04, 3.90) 0.036
Log10 glucose 1.45 4.27 (1.88, 9.69) 0.0005
Ever smoked 0.994 2.70 (1.03, 7.10) 0.044
cirrhosis ( p = 0.024) were all positively associated with duo-
denal ulcer.
DISCUSSION
The overall prevalence of PHG in this highly selected study
population was 37%, a proportion which is consistent with
other cross-sectional studies involving patients with ad-
vanced but compensated chronic liver disease (2, 6). The
lower frequency of severe compared to mild PHG is also con-
sistent with prior studies (2, 6, 18). The current study also
demonstrated a strong positive association between the pres-
ence of PHG and esophageal varices (Fig. 3) (2, 9). The cur-
rent study was unique in that it represents a large prospective
cohort of well-characterized HCV patients who have under-
gone surveillance EGD. The presence and severity of PHG
was graded in a standardized manner using a validated scoring
system (18). In addition, all liver biopsies were reviewed by
a central group of expert hepatopathologists and all patients
underwent extensive laboratory and clinical assessment upon
study entry. The prevalence and correlates of PHG from this
study are likely to be representative of American patients with
advanced but compensated HCV who have failed to respond
to pegylated interferon and ribavirin.
The pathogenesis of PHG is not well understood but may be
related to increased gastric mucosal blood flow mediated by
activation of cytokines and growth factors (11, 19, 20). There
is no established link between Helicobacter pylori infection
and the presence and severity of PHG (21, 22). Hemodynamic
studies demonstrate that the severity of portal hypertension
is related to the likelihood of having severe PHG but is not
the sole determinant (19, 23). In particular, portal pressure
measurements do not correlate with the presence or sever-
ity of GAVE and several authors have suggested alternative
etiopathogenic mechanisms for GAVE (5, 24, 25). A recent
study demonstrated that subjects with acute heavy alcohol in-
gestion were more likely to have gastroduodenal erosions and
ulcers that were independently associated with the presence
and severity of PHG (26). In the current study, however, no as-
sociation was found between either lifetime or recent alcohol
consumption and the prevalence or severity of PHG (Table 2).
This lack of association may have been due to the fact that
most of the HALT-C patients (86%) were abstinent from alco-
hol at enrollment and the few who did consume alcohol were
drinking minimally. Similarly, the current study also failed to
demonstrate a relationship between NSAID and/or COX-2
inhibitor use and the presence or severity of PHG. Finally, al-
though smoking has been associated with changes in gastric
mucosal blood flow and mucosal ulceration, an association
between PHG and smoking was not identified in this study
cohort.
The expected associations between markers of liver disease
severity and the presence and severity of PHG were identified
on both univariate and multivariate analysis (Tables 2 and 3).
In a logistic regression model, only non-African American
race, low platelet count, high serum bilirubin, low serum
Figure 3. Prevalence of small, medium, and large esophageal varices
in patients with and without portal hypertensive gastropathy (PHG)
( p < 0.0001).
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albumin, and high glucose levels were found to be indepen-
dent predictors of PHG. The reduced probability of African
Americans having PHG is consistent with a prior analysis of
this cohort in which African Americans were significantly
less likely to have esophageal varices (17). The mechanism
for a protective effect of race is not clear and the clinical
significance is uncertain since PHG was identified in 35%
of African Americans and 39% of non-African Americans.
However, the prevalence of cirrhosis was lower (35% vs 43%,
p = 0.0459) and the mean platelet counts were higher (180
vs 161 103/mL, p = 0.0003) among African American com-
pared to non-African American HALT-C patients. The asso-
ciation between glucose levels and the presence and severity
of PHG may relate to an increased frequency of glucose in-
tolerance and insulin resistance among HCV patients with
more severe hepatic fibrosis (27). Fibrotic remodeling of the
liver can lead to reduced clearance of insulin and insulin-
like growth factors with resultant splanchnic hyperinsuline-
mia that may stimulate hepatic stellate cells (27, 28). Several
studies have also demonstrated increased rates of fibrosis pro-
gression among HCV patients with hepatic steatosis and in-
sulin resistance (29, 30). Therefore, it is possible that the sig-
nificant association between glucose levels and the presence
and severity of PHG may reflect changes due to underlying
insulin resistance but further physiologic studies are needed
(31–34).
The prevalence of mild (3%) and severe (1%) GAVE was
low in this highly selected patient population. This may in
part be due to the predominance of men and the intentional
exclusion of patients with a history of gastrointestinal bleed-
ing or anemia at entry. In addition, only GAVE lesions lo-
calized to the antrum in a stripe-like appearance were scored
while prior studies have suggested that vascular ectasias in
patients with cirrhosis are more likely to be diffuse and lo-
cated in the body (24, 35). On multivariate modeling, both
increased serum bilirubin and glucose levels were positively
associated with the presence of GAVE as were the recent use
of an NSAID and a lifetime history of smoking. It is well-
known that NSAIDs can induce gastroduodenal erosions and
ulcers and that NSAID gastropathy tends to localize to the
antrum possibly due to motility effects (36). Interestingly,
some studies have suggested that patients with cirrhosis and
GAVE may display abnormal antral motility (37). Although
GAVE lesions represent a distinct clinicopathological entity,
the positive association of NSAID use with GAVE lesions in
this patient population is consistent with prior work demon-
strating reduced gastric mucosal gel thickness in patients with
PHG and increased susceptibility to caustic agents (38, 39).
Similarly, the well described epidemiological association be-
tween smoking and gastroduodenal ulceration may, in part,
account for the positive association noted between smoking
and GAVE (40–44).
Identifying risk factors for bleeding from PHG is difficult
due to the low rate of spontaneous bleeding from this entity
(7, 18). During longitudinal follow-up, subjects with severe
PHG are more likely to bleed than subjects with mild PHG
(6, 18). In addition, HCV patients with cirrhosis and severe
PHG were more likely to have a peptic ulcer compared to pa-
tients with mild PHG (22). In the current study, however, there
was no significant relationship between baseline hemoglobin
or iron levels with the presence or severity of PHG or the
presence of GAVE lesions (data not shown). These obser-
vations may be due, in part, to the intentional exclusion of
subjects with a prior history of gastrointestinal bleeding or
anemia at entry. Further study and follow-up should demon-
strate whether patients with PHG and/or GAVE features are
more likely to develop gastrointestinal bleeding during the
randomized phase of HALT-C.
Limitations of this study included the lack of central re-
view of endoscopic photos for PHG grading (45). However,
all endoscopists were trained on the scoring system and a
standardized reporting form and manual of procedures were
used at participating sites. The optimal means of scoring PHG
remains controversial since few studies have demonstrated a
relationship between PHG severity and the risk of gastroin-
testinal bleeding (2, 18, 45). The PHG scoring system used
in this study has been shown to have excellent interobserver
agreement and to correlate with the risk of bleeding during
short-term follow-up (18). However, as with other proposed
PHG scoring systems, there is a lower interobserver agree-
ment on scoring the severity of PHG using the NIEC crite-
ria. Portal hemodynamic studies were not performed in this
study because of the associated risks and resources required.
However, prior studies that have attempted to correlate portal
hemodynamic measurements with endoscopic findings have
yielded inconsistent results (11, 19). Finally, subjects enrolled
in HALT-C are not necessarily representative of HCV pa-
tients with advanced fibrosis in the general population since
subjects with anemia, severe thrombocytopenia, or other con-
traindications to retreatment with pegylated IFN and ribavirin
were excluded. In addition, subjects with a prior history of
gastrointestinal bleeding, ascites, or encephalopathy were ex-
cluded. Nonetheless, this study represents the largest cohort
of well-characterized American subjects with advanced but
compensated HCV fibrosis who have undergone surveillance
EGD.
In summary, 37% of 1,016 HCV patients with bridging
fibrosis or compensated cirrhosis had evidence of PHG but
only 3% had severe PHG. Independent correlates of PHG
include biochemical markers of liver disease severity (low
serum albumin, high bilirubin), portal hypertension (low
platelet count), and markers of insulin resistance (high glu-
cose levels). Subjects with a prior history of smoking and
recent NSAID use were found to be at greatest risk of har-
boring GAVE but the low overall prevalence of this lesion
limits the strength and implications of this finding. The clin-
ical significance of PHG and GAVE as a source of gastroin-
testinal bleeding and as a potential correlate of disease pro-
gression will be tracked during the longitudinal phase of
HALT-C.
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STUDY HIGHLIGHTS
What Is Current Knowledge The clinical significance of portal hypertensive gas-
tropathy is unclear due to the lack of large, prospec-
tive studies involving well-characterized patients with
varying severity of liver disease.
What Is New Here The HALT-C trial demonstrates that 37% hepatitis C
virus (HCV) patients with bridging fibrosis or compen-
sated cirrhosis on liver biopsy have portal hypertensive
gastropathy that was severe in only 3%. The mucosal mosaic pattern was the most commonly
identified upper endoscopic features (33%) followed
by red marks (15%) and gastric antral vascular ectasia
(GAVE) (3%). Both mild and severe portal hypertensive gastropathy
were significantly associated with the stage of hepatic
fibrosis. Patients with portal hypertensive gastropathy were sig-
nificantly more likely to have esophageal varices com-
pared to subjects without portal hypertensive gastropa-
thy and to have medium/ large varices. However, the
mean hemoglobin levels and iron stores were similar
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in patients with and without portal hypertensive gas-
tropathy. Independent predictors of portal hypertensive gas-
tropathy include biochemical markers of liver disease
severity (serum albumin, bilirubin), portal hyperten-
sion (platelet count), insulin resistance (glucose), and
non-African American race. Contrary to expectations, lifetime smoking and alcohol
consumption as well as NSAID use are not associated
with mild or severe portal hypertensive gastropathy.
However, lifetime smoking and NSAID use in the past
year were significantly associated with the presence of
GAVE.
Reprint requests and correspondence: Robert J. Fontana, M.D.,
3912 Taubman Center, Ann Arbor, MI 48109-0362.
Received July 26, 2005; accepted November 4, 2005.
REFERENCES
1. Burak KW, Lee SS, Beck PL. Portal hypertensive gas-
tropathy and gastric antral vascular ectasia syndrome. Gut
2001;49:866–72.
2. Thuluvath PJ, Yoo HY. Portal hypertensive gastropathy. Am
J Gastroenterol 2002;97:2973–8.
3. Carpinelli C, Primignani M, Preatoni P, et al. Portal hy-
pertensive gastropathy: Reproducibility of a classification,
prevalence of elementary lesions, sensitivity and specificity
in the diagnosis of cirrhosis of the liver. A NIEC multicenter
study. Ital J Gastroenterol 1997;29:533–40.
4. Sarin SK. Diagnostic issues: Portal hypertensive gastropathy
and gastric varices. In Portal Hypertension II. Proceedings
of the second Baveno International consensus workshop on
definitions, methodology and therapeutic strategies. R De-
Franchis, ed. Oxford; Blackwell Science, 1996:30–55.
5. Payen JL, Cales P, Voigt JJ, et al. Severe portal hypertensive
gastropathy and antral vascular ectasia are distinct entities
in patients with cirrhosis. Gastroenterology 1995;108:134–
44.
6. Merli M, Nicolini G, Angeloni S, et al. The natural his-
tory of portal hypertensive gastropathy in patients with liver
cirrhosis and mild portal hypertension. Am J Gastroenterol
2004;99:1959–65.
7. Primignani M, Carpinelli L, Preatoni P, et al. Natural
history of portal hypertensive gastropathy in patients with
liver cirrhosis. Gastroenterology 2000;119:181–7.
8. Gupta R, Saraswat VA, Kumar M, et al. Frequency and fac-
tors influencing portal hypertensive gastropathy and duo-
denopathy in cirrhotic portal hypertension. J Gastro Hepatol
1996;11:728–33.
9. Sarin SK, Shahi HM, Jain M, et al. The natural history of
portal hypertensive gastropathy: Influence of variceal erad-
ication. Am J Gastroenterol 2000;95:2888–93.
10. Gostout CJ, Viggiano TR, Balm RK. Acute gastrointestinal
bleeding from portal hypertensive gastropathy: Prevalence
and clinical features. Am J Gastroenterol 1993;88:2030–
3.
11. Ohta M, Yamaguchi S, Gotoh N, et al. Pathogenesis of por-
tal hypertensive gastropathy: A clinical and experimental
review. Surgery 2002;131:S165–70.
12. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the
HALT-C trial: Pegylated interferon as a maintenance therapy
for chronic hepatitis C in previous interferon nonresponders.
Control Clin Trials 2004;25:472–92.
13. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Pegin-
terferon alfa-2a and ribavirin in patients with chronic
hepatitis C who failed prior treatment. Gastroenterology
2004;126:1015–23.
14. Skinner HA, Sheu WJ. Reliability of alcohol use indices:
The lifetime drinking history and the MAST. J Stud Alcohol
1982;43:1157–70.
15. Ishak KG. Chronic hepatitis: Morphology and nomencla-
ture. Mod Pathol 1994;7:690–713.
16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis
model assessment: Insulin resistance and beta-cell function
from fasting plasma glucose and insulin concentrations in
man. Diabetologia 1985;28:412–9.
17. Sanyal AJ, Fontana RJ, Wright E, the Hepatitis C Anti-viral
Long-term Treatment Against Cirrhosis (HALT-C) trial in-
vestigators. The presence and spectrum of varices in the
absence of cirrhosis in patients with chronic hepatitis C (Ab-
stract). Hepatology 2003;38(suppl 1):218A.
18. Stewart CA, Sanyal AJ. Grading portal gastropathy: Vali-
dation of a gastropathy scoring system. Am J Gastroenterol
2003;98:1758–65.
19. Trevino HH, Brady CE, Schenker S. Portal hypertensive
gastropathy. Dig Dis 1996;14:258.
20. Ohta M, Yamaguchi S, Gotoh N, et al. Pathogenesis of por-
tal hypertensive gastropathy: A clinical and experimental
review. Surgery 2002;131(suppl 1):S165–70.
21. Parikh SS, Desai SB, Prabhu SR, et al. Congestive gastropa-
thy: Factors influencing development, endoscopic findings,
Helicobacter pylori infection and microvessel changes. Am
J Gastroenterol 1994;89:1036–42.
22. Dore MP, Mura D, Deledda S, et al. Active peptic ulcer dis-
ease in patients with hepatitis C virus-related cirrhosis: The
role of Helicobacter pylori infection and portal hypertensive
gastropathy. Can J Gastroenterol 2004;18:521–4.
23. Merkel C, Schipilliti M, Bighin R, et al. Portal hypertension
and portal hypertensive gastropathy in patients with liver cir-
rhosis: A haemodynamic study. Dig Liver Dis 2003;35:269–
74.
24. Ito M, Uchida Y, Kamano S, et al. Clinical comparisons
between two subsets of gastric antral vascular ectasia. Gas-
trointest Endosc 2001;53:764.
25. Spahr L, Villeneuve JP, Dufresne MP, et al. Gastric antral
vascular ectasia in cirrhotic patients: Absence of relation
with portal hypertension. Gut 1999;44:739–42.
26. Auroux J, Lamarque D, Roudot-Thoraval F, et al. Gastro-
duodenal ulcer and erosions are related to portal hyperten-
sive gastropathy and recent alcohol intake in cirrhotic pa-
tients. Dig Dis Sci 2003;48:1118–23.
27. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and
hyperinsulinemia stimulate connective tissue growth fac-
tor expression: A potential mechanism involved in progres-
sion to fibrosis in non-alcoholic steatohepatitis. Hepatology
2001;34:738–44.
28. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non-
alcoholic steatohepatitis: Association of insulin resis-
tance and mitochondrial abnormalities. Gastroenterology
2001;120:1183–92.
29. Hourigan LF, Macdonald GA, Purdie D, et al. Fibro-
sis in chronic hepatitis C correlates significantly with
body mass index and steatosis. Hepatology 1999;29:1215–
9.
30. Adinolfi LE, Gambardella M, Andreana A, et al. Steato-
sis accelerates the progression of liver damage of chronic
992 Fontana et al.
hepatitis C patients and correlates with specific HCV geno-
type and visceral obesity. Hepatology 2001;33:1358–64.
31. Uygun A, Kadayifci A, Yesilova Z, et al. Serum leptin lev-
els in patients with non-alcoholic steatohepatitis. Am J Gas-
troenterol 2000;95:3584–9.
32. Saxena NK, Floyd GJ, Anania FA. Leptin is an independent
agonist in the transcriptional activation of the alpha(1) col-
lagen gene in hepatic stellate cells (Abstract). Hepatology
2001;34:359A.
33. Ruhl CE, Everhart JE. Determinants of the association
of overweight with elevated serum alanine aminotrans-
ferase activity in the United States. Gastroenterology
2003;124:71–9.
34. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectine-
mia in obesity and type 2 diabetes mellitus: Close associ-
ation with insulin resistance and hyperinsulinemia. J Clin
Endocrinol Metab 2001;86:1920–35.
35. Dulai GS, Jensen DM, Kovacs TOG, et al. Endoscopic treat-
ment outcomes in watermelon stomach patients with and
without portal hypertension. Endoscopy 2004;36:68–72.
36. Lanza FL. A guideline for the treatment and prevention of
NSAID-induced ulcers. Am J Gastroenterol 1998;93:2037.
37. Charneau J, Petit R, Cales P, et al. Antral motility in patients
with cirrhosis with or without gastric antral vascular ectasia.
Gut 1995;37:488–92.
38. Tanoue K, Tarnawski AS, Kishihiara F, et al. Effect of
teprenone on portal hypertensive gastric mucosa. Digestion
1996;57:35–40.
39. Giofre MR, Meduri G, Pallio S, et al. Gastric permeability
to sucrose is increased in portal hypertensive gastropathy.
Eur J Gastroenterol Hepatol 2000;12:529–33.
40. Schoon IM, Mellstrom D, Oden A, et al. Peptic ulcer disease
in older age groups in Gothenburg in 1985: The association
with smoking. Age Ageing 1991;20:371.
41. Murata JH, Nogawa AN. Meta-analysis of risk factors
for peptic ulcer. Nonsteroidal anti-inflammatory drugs,
Helicobacter pylori, and smoking. J Clin Gastroenterol
1997;24:2.
42. Wang CS, Wang ST, Chang TT, et al. Smoking and alanine
aminotransferase levels in hepatitis C virus infection. Arch
Intern Med 2002;162:811–5.
43. Pessione F, Ramond MJ, Njapoum C, et al. Cigarette smok-
ing and hepatic lesions in patients with chronic hepatitis C.
Hepatology 2001;34:121–5.
44. Siringo S, Burroughs AK, Bolondi L, et al. Peptic ulcer and
its course in cirrhosis an endoscopic and clinical prospective
study. J Hepatol 1995;22:633–41.
45. Yoo HY, Eustace JA, Verma S, et al. Accuracy and relia-
bility of the endoscopic classification of portal hypertensive
gastropathy. Gastrointest Endosc 2002;56:675–80.
